0
0
In a remarkable display of resilience, scientists at Israel’s Weizmann Institute of Science have published a major breakthrough in leukemia diagnostics just days after their labs were damaged in an Iranian missile strike.
On June 15, Iranian ballistic missiles struck the Weizmann Institute in Rehovot, causing extensive destruction. The Cancer Research Unit was among the hardest hit, with entire labs and years of irreplaceable research lost. Despite this setback, Professors Liran Shlush and Amos Tanay, co-leads of a joint research project, announced a discovery that could revolutionize the diagnosis and treatment of leukemia, a notoriously aggressive cancer of the blood.
A Leap Forward in Leukemia Diagnosis
Traditionally, leukemia diagnosis requires a bone marrow biopsy—a painful and invasive procedure. Shlush and Tanay’s team challenged this paradigm by focusing on free-floating stem cells in the bloodstream. Their research demonstrated that these rare cells, previously believed to reside only in bone marrow, are present in small numbers in all adults. By analyzing their abundance and genetic abnormalities, the team developed a method to accurately diagnose leukemia using a simple blood test. This innovation could make bone marrow biopsies obsolete and allow for earlier, less invasive detection of the disease.
“We characterized [stem cells in the bloodstream] in a unique way, for the first time across hundreds of people, and created the first reference range [for healthy adults],” said Professor Shlush. “Now we can compare the cells of a patient to the norm, and define all the unique abnormalities… Instead of doing bone marrow biopsies that are used to diagnose [leukemia], we can diagnose from the peripheral blood”.
Science Amidst Adversity
The missile strike, which occurred at 3 a.m. as Israelis sheltered from attack, destroyed years of research and about 25% of the team’s collected stem cell samples—resources that are irreplaceable. Despite being unable to access their lab, the Weizmann community rallied, sharing space and resources to keep the research moving forward.
The breakthrough paper was published in Nature Medicine just days after the attack. Shlush and Tanay have already begun the next phase: a large-scale clinical trial to determine if their blood test can predict leukemia before symptoms appear. Clinics in the United States, Taiwan, and Europe have joined the project, and the team hopes their work will soon make non-invasive leukemia diagnosis standard practice worldwide.
Looking Ahead
The researchers are also working to adapt their technique for pediatric patients, particularly those with a genetic predisposition to leukemia, aiming to spare children from annual bone marrow biopsies.
Professor Shlush credited the success to the collaboration with mathematician Professor Tanay and the dedication of their students and colleagues, emphasizing the importance of teamwork in scientific progress.
“While Israel fought the Iranian enemy, Shlush, Tanay and their team advanced the fight against cancer—and they scored a win.”
Disclaimer:
This article is based on currently available information and recent scientific publications. The described diagnostic method for leukemia, while promising, is still undergoing clinical trials and has not yet become standard medical practice. Patients should consult healthcare professionals for medical advice and rely on approved diagnostic procedures until new methods are fully validated and widely adopted.
